Key Performance
More- Earnings Score: N/A
- Momentum Score: 31
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Radiopharm Theranostics Reports Business Update
Radiopharm Theranostics completed enrollment in its Phase 2b trial for RAD 101, an imaging agent for brain metastases, with interim data showing 90% concordance with MRI. The company also presented Phase 0/1 data for RAD 202 showing favorable safety and tumor uptake, received DSMC approval to advance to the next dose level, and initiated two new First-In-Human trials for radiotherapeutic assets RV-01 and RAD 402. Cash position declined to $19.2 million from $34.5 million in the prior quarter.
04/23/2026, 7:00 AM • GlobeNewswire
Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Radiopharm Theranostics received a positive recommendation from its Data Safety and Monitoring Committee to escalate its Phase 1 'HEAT' clinical trial of RAD202 to the next dose level of 130mCi in HER2-positive advanced solid tumor patients. The company remains on track to complete Phase 1 dose escalation by end of 2026.
04/08/2026, 7:00 AM • GlobeNewswire
Radiopharm Theranostics and Siemens Healthineers announced a supply agreement for RAD101, a novel PET imaging agent for brain metastases. The Phase 2b interim analysis showed 90% concordance with MRI (primary endpoint), with significant tumor uptake. Siemens will manufacture and distribute 18F-labeled RAD101 to support the upcoming Phase 3 registrational trial in the U.S.
04/07/2026, 7:00 AM • GlobeNewswire
Radiopharm Theranostics announced the first patient dosing in a Phase 1 clinical trial of RAD 402, a monoclonal antibody targeting KLK3 radiolabelled with Terbium 161 for advanced prostate cancer treatment. Preclinical data showed strong tumor targeting with minimal bone/marrow uptake. The company plans to share data from the first two dose levels in H2 2026.
03/27/2026, 7:00 AM • GlobeNewswire
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Radiopharm Theranostics announced interim Phase 2b results for RAD 101, with 92% of evaluable patients achieving the primary endpoint of MRI concordance in brain metastases imaging. The company also reported progress across its pipeline including DSMC approval for dose escalation in RAD 202 and RAD 204, FDA clearance for Phase 1 trials of RV 01 and RAD 402, and cash reserves of $34.52 million providing runway into 2027.
01/28/2026, 7:00 AM • GlobeNewswire
Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream
EmergingGrowth.com has announced the complete schedule for the 89th Emerging Growth Conference taking place on January 21-22, 2026. The two-day virtual event will feature presentations from 40+ small-cap and emerging growth companies across sectors including biotech, mining, energy, and technology. Companies will present via video webcast with keynote speakers from each organization.
01/21/2026, 7:00 AM • GlobeNewswire
RAD Increases Ownership in Radiopharm Ventures to 87.5%
Radiopharm Theranostics increased its ownership stake in Radiopharm Ventures (joint venture with MD Anderson Cancer Center) from 75% to 87.5%. The leading candidate Betabart, a B7H3-targeting monoclonal antibody, received FDA IND clearance and is expected to dose the first patient in Q1 2026 in a Phase I trial for solid tumors. Two additional preclinical assets show early positive results with final candidate selection planned for 2026.
01/12/2026, 7:00 AM • GlobeNewswire
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
Radiopharm Theranostics has appointed Dr. Oliver Sartor, a renowned medical oncologist specializing in prostate cancer and radiopharmaceutical therapies, to its Scientific Advisory Board to enhance its clinical research capabilities.
07/22/2025, 8:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.